Merck & Co Inc

NYSE: MRK
$103.39
+$1.77 (+1.7%)
Real Time Data Delayed 15 Min.

MRK Articles

The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
Judging by the most shorted stocks traded on the New York Stock Exchange between the October 15 and October 31 settlement dates, those sellers had become more selective.
Drugmaker Merck wrestled away from Apple the top ranking last week as the best performing stock among the Dow 30.
Apple, Intel, Pfizer, and Merck were the worst performing Dow stocks on Friday.
Merck shares were up slightly on Wednesday after the pharma giant gave another key update for its KEYTRUDA line. The firm announced that the U.S. Food and Drug Administration (FDA) has approved...
Many market experts worry that poor earnings and a slowing economy could beat down the market between now and the end of the year. But two Dow stocks show no signs of surrendering their healthy gains.
What makes sense for investors now is safe stocks that pay dividends and provide products or services that will continue to be bought or used regardless of what the overall equity market does.
Apple returns for another week as the top-performing Dow stock for the year to date even though shares dropped nearly 1.5% in another week of losses in U.S. equities markets.
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Pharmaceutical maker Merck beat adjusted earnings estimates but missed slightly on revenues when it reported Q3 results Thursday morning. Investors responded positively, however.
These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices for worried investors to consider...
24/7 Wall St. has put together a preview of Boeing, Intel, Verizon and the other Dow companies scheduled to report their quarterly results this week.
Apple shares dipped again last week, but the company managed to hold onto its rank as the top-performing Dow stock for the year to date. Shares are up nearly 30% in 2018.
Merck shares were up handily on Tuesday after the company announced a key update from the FDA on its Lynparza for the treatment of pancreatic cancer.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Adobe, Bank of America, Boston Scientific, Facebook, Las Vegas Sands, Merck, Tilray, TJX Companies and Valero Energy.